Cover Image
Market Research Report
Product code 
1058129

Rheumatoid Arthritis (RA) Therapy Area Report

Published: | Lumanity | 65 Pages | Delivery time: 1-2 business days

Price

Back to Top
Rheumatoid Arthritis (RA) Therapy Area Report
Published: February 16, 2022
Lumanity
Content info: 65 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

Our latest report provides insights into the Rheumatoid Arthritis (RA) online landscape, from the perspective of multiple stakeholders, and offers an evaluation of the extensive competitive landscape in this space. It identifies and provides a detailed overview of present and developing patient needs, hot topics of conversation amongst physicians, and prominent digital opinion leaders. Additionally, the report will help assess how pharma companies are utilising social media to engage in RA discussions, and understand ways in which to best connect with and support key customers.

Table of Contents

Introduction

  • Executive Summary, Methodology and Background

RA Social Media Landscape Overview

  • Social Media Conversation Architecture

The Patient Voice

  • Patient Audiences in RA
  • Key Topics of Patient Conversation
  • Disease Experiences:
    • Diagnosis
    • Unmet Needs in Young Adult / Pregnant Women
    • Mental Health Impact
    • COVID-19 and RA
  • Treatment Experiences:
    • Brand Discussion
    • Treatment Switching
    • Safety Discussions
    • JAKiSafety Discussion and Key Questions Asked
    • Mode of Administration
    • Remission Discussion
  • Summary and Opportunities from the Patient Conversation

Clinical Conversations

  • Physician Online Audiences
  • Key Topics of Physician Conversation
  • Physician Views on JAKiSafety
  • Key Conference SoV
  • EULAR 2021 Discussions
  • ACR 2021 Discussions
  • Top Digital Opinion Leaders in RA
  • Summary and Opportunities from the Physician Conversation

Competitive Intelligence

  • Summary of Key Company Online Performance
  • Key Company Social Media Presence
  • Company Social Media Activity Overview:
    • UCB
    • Galapagos
    • BMS
    • Amgen
    • Pfizer
    • Sanofi
    • AbbVie
    • Genentech
    • Janssen
    • Eli Lilly
  • Summary and Opportunities from the Pharma Conversation

Companies mentioned :

  • 1. Pfizer
  • 2. Janssen
  • 3. Amgen
  • 4. Johnson & Johnson
  • 5. Bristol Myers Squibb
  • 6. Sanofi
  • 7. Eli Lilly
  • 8. Genentech
  • 9. Amgen
  • 10. AbbVie
  • 11. Merck
  • 12. Roche
  • 13. UCB
  • 14. Regeneron
  • 15. Galapagos
  • 16. Boehringer Ingelheim
  • 17. GSK
  • 18. Abivax
  • 19. R-Pharm
  • 20. Lupin
  • 21. Mylan
  • 22. Sandoz
  • 23. Samsung Bioepis
  • 24. Nichi-Iko Pharmaceutical
  • 25. Teva
  • 26. Dr. Reddy's Laboratories
  • 27. Archigen Biotech Limited
  • 28. Biogen
  • 29. FujiFilm
  • 30. Alvotech
  • 31. Coherus Biosciences

Products mentioned:

  • 1. JNJ-67484703
  • 2. Nivolumab
  • 3. PF-06835375
  • 4. ABBV-154
  • 5. ABBV-3373
  • 6. Fenebrutinib
  • 7. LY3462817
  • 8. Otilimab
  • 9. Olokizumab
  • 10. ABX464
  • 11. Humira
  • 12. Remicade
  • 13. Kevzara
  • 14. Orencia
  • 15. Olumiant
  • 16. Xeljanz
  • 17. Jyseleca
  • 18. Rinvoq
  • 19. Rituxan
  • 20. Simponi
  • 21. Cimzia
  • 22. Actemra
  • 23. Benepali
  • 24. Brenzys
  • 25. Eticovo
  • 26. Erelzi
  • 27. Nepexto
  • 28. YLB-113
  • 29. Inflectra
  • 30. Zessly
  • 31. Renflexis
  • 32. Flixabi
  • 33. Avsola
  • 34. NI-071
  • 35. Truxima
  • 36. Ruxience
  • 37. ABP-798
  • 38. SAIT-101
  • 39. Reditux
  • 40. Amjevita
  • 41. Cyltezo
  • 42. Imraldi
  • 43. Hulio
  • 44. Hyrimo
  • 45. Abrilada
  • 46. MSB-11022
  • 47. AVT-02
  • 48. CHS-1420